J Liver Cancer.  2023 Mar;23(1):124-126. 10.17998/jlc.2023.3.7.

Impact of the updated KLCA-NCC criteria for diagnosis of “probable HCC” in liver MRI: comparisons between KLCA v2022 and v2018

• Yoon JH

• KMID: 2540825
• DOI: http://doi.org/10.17998/jlc.2023.3.7

Reference

References

1. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC). 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol. 2022; 23:1126–1240.

2. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC). 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol. 2019; 20:1042–1113.

3. Joo I, Lee JM, Koh YH, Choi SH, Lee S, Chung JW. 2022 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for imaging diagnosis of hepatocellular carcinoma: what's new? Korean J Radiol. 2023; 24:1–5.

4. Agnello F, Albano D, Sparacia G, Micci G, Matranga D, Toia P, et al. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up. Clin Imaging. 2020; 68:169–174.

5. Cannella R, Vernuccio F, Sagreiya H, Choudhury KR, Iranpour N, Marin D, et al. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Eur Radiol. 2020; 30:3770–3781.

6. Yoon JK, Lee S, Hwang JA, Lee JE, Kim S, Kim MJ. Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria. J Liver Cancer. 2023; 23:157–165.

7. Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology. 2013; 267:776–786.